Literature DB >> 15609189

A single European currency for EQ-5D health states. Results from a six-country study.

Wolfgang Greiner1, Tom Weijnen, Martin Nieuwenhuizen, Siem Oppe, Xavier Badia, Jan Busschbach, Martin Buxton, Paul Dolan, Paul Kind, Paul Krabbe, Arto Ohinmaa, David Parkin, Montserat Roset, Harri Sintonen, Aki Tsuchiya, Frank de Charro.   

Abstract

The EQ-5D questionnaire is a widely used generic instrument for describing and valuing health that was developed by the EuroQol Group. A primary objective of the EuroQol Group is the investigation of values for health states in the general population in different countries. As part of the EuroQol enterprise 11 population surveys were carried out in six Western European countries (Finland, Germany, The Netherlands, Spain, Sweden and the UK) to value health states as defined by the EQ-5D using a standardised visual analogue scale (EQ-5D VAS). This contribution reports how a European set of general population preference weights was derived from the data collected in the 11 valuation studies. The scores from this set of preference weights can be applied to generate a VAS-based weighted health status index for all the potential 243 EQ-5D health states for use in multi-national studies. To estimate the preference weights a multi-level regression analysis was performed on 82,910 valuations of 44 EQ-5D health states elicited from 6,870 respondents. Stable and plausible solutions were found for the model parameters. The R(2) value was 75%. The analysis showed that the major source of variance, apart from 'random error', was variance between individuals (28.3% of the total residual variance). These results suggest that VAS values for EQ-5D health states in six Western European countries can be described by a common model.

Year:  2003        PMID: 15609189     DOI: 10.1007/s10198-003-0182-5

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  143 in total

1.  The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries.

Authors:  Raymond Oppong; Billingsley Kaambwa; Jacqueline Nuttall; Kerenza Hood; Richard D Smith; Joanna Coast
Journal:  Eur J Health Econ       Date:  2011-11-05

2.  New model to explain the EQ-5D VAS in patients who have undergone spinal fusion.

Authors:  Jorge Cortés; Juan F Blanco; David Pescador; Nuria Asensio; Claudio Castro; Juan Moncada Herrera
Journal:  Qual Life Res       Date:  2010-08-09       Impact factor: 4.147

3.  [Multimorbidity and successful aging: the population-based KORA-Age study].

Authors:  A Peters; A Döring; K-H Ladwig; C Meisinger; B Linkohr; C Autenrieth; S E Baumeister; J Behr; A Bergner; H Bickel; M Bidlingmaier; A Dias; R T Emeny; B Fischer; E Grill; L Gorzelniak; H Hänsch; S Heidbreder; M Heier; A Horsch; D Huber; R M Huber; R A Jörres; S Kääb; S Karrasch; I Kirchberger; G Klug; B Kranz; B Kuch; M E Lacruz; O Lang; A Mielck; D Nowak; S Perz; A Schneider; H Schulz; M Müller; H Seidl; R Strobl; B Thorand; R Wende; W Weidenhammer; A-K Zimmermann; H-E Wichmann; R Holle
Journal:  Z Gerontol Geriatr       Date:  2011-12       Impact factor: 1.281

4.  US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?

Authors:  I-Chan Huang; Richard J Willke; Mark J Atkinson; William R Lenderking; Constantine Frangakis; Albert W Wu
Journal:  Qual Life Res       Date:  2007-04-06       Impact factor: 4.147

5.  Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study.

Authors:  B Al-Nawas; C Walter; T Morbach; N Seitner; E Siegel; M Maeurer; F Krummenauer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-29       Impact factor: 3.267

6.  The valuation of the EQ-5D in Portugal.

Authors:  Lara N Ferreira; Pedro L Ferreira; Luis N Pereira; Mark Oppe
Journal:  Qual Life Res       Date:  2013-06-08       Impact factor: 4.147

Review 7.  Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Authors:  Karla M Eggert; Jens P Reese; Wolfgang H Oertel; Richard Dodel
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.

Authors:  Paul A Scuffham; Jennifer A Whitty; Andrew Mitchell; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Quality-of-life loss of people admitted to burn centers, United States.

Authors:  Ted Miller; Soma Bhattacharya; William Zamula; Dennis Lezotte; Karen Kowalske; David Herndon; James Fauerbach; Loren Engrav
Journal:  Qual Life Res       Date:  2012-12-08       Impact factor: 4.147

10.  Low back pain and health-related quality of life in community-dwelling older adults.

Authors:  C Cedraschi; C Luthy; A F Allaz; F R Herrmann; C Ludwig
Journal:  Eur Spine J       Date:  2016-03-07       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.